Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma.

doi:10.1038/sj.leu.2401315

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma.

Leukemia - 1 Mar 1999

Møller M B, Ino Y, Gerdes A M, Skjødt K, Louis D N, Pedersen N T

Abstract excerpt

The two gene products of the CDKN2A gene, p16 and p19ARF, have recently been linked to each of two major tumour suppressor pathways in human carcinogenesis, the RB1 pathway and the p53 pathway. p16 inhibits the phosphorylation of the retinoblastoma gene product by cyclin D-dependent kinases, whereas p19ARF targets MDM2, a p53 inhibitory protein, for degradation. A deletion of CDKN2A would therefore disturb both...

Topics

Cyclin-Dependent Kinase Inhibitor p16
DNA Methylation
Humans
Immunohistochemistry
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse
Mutation
Nuclear Proteins
Promoter Regions, Genetic
Proto-Oncogene Proteins
Proto-Oncogene Proteins c-mdm2
Tumor Suppressor Protein p53

Source

Open in PubMed

Identifiers

PMID: 10086736
DOI: 10.1038/sj.leu.2401315

Genes

MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics